PARP Inhibitor–based Combinations for the Management of Patients with Metastatic Castration-resistant Prostate Cancer: What Are the Data Telling Us?

PARP Inhibitor–based Combinations for the Management of Patients with Metastatic Castration-resistant Prostate Cancer: What Are the Data Telling Us? is organized by Med Learning Group.,Release Date: May 31, 2022,Expiration Date: May 31, 2023,Program Overview:,This enduring activity has been designed for HCPs treating metastatic castration-resistant prostate cancer (mCRPC) to improve: knowledge of the mechanisms of action of PARP inhibitor-based combinations for the treatment of patients with mCRPC with or without DNA damage response (DDR) alterations; awareness of new clinical data on the efficacy, safety, and tolerability of emerging PARP inhibitor-based combinations with different mechanisms of action for the treatment of patients with mCRPC; and their ability to develop individualized management plans for patients with mCRPC with or without DDR alterations that include PARP inhibitor-based combinations if appropriate.,Learning Objectives:,Upon the completion of this program, attendees should be able to:,• Support the biological and clinical rationale for the use of PARP inhibitor-based combinations for the treatment of mCRPC with or without DDR alterations,• Interpret evidence from clinical trials assessing the efficacy, safety, and tolerability of emerging PARP inhibitor-based combinations with different mechanisms of action for the treatment of mCRPC,• Develop management plans that are individualized for patients with mCRPC with or without DDR alterations that include PARP inhibitor-based combinations if appropriate